NRXP
Price
$3.04
Change
-$0.12 (-3.79%)
Updated
Oct 16, 04:59 PM (EDT)
Capitalization
72.26M
Intraday Buy/Sell Signals
RNAC
Price
$9.41
Change
-$0.24 (-2.49%)
Updated
Oct 16, 04:59 PM (EDT)
Capitalization
244.94M
Intraday Buy/Sell Signals
Interact to see
Advertisement

NRXP vs RNAC

Header iconNRXP vs RNAC Comparison
Open Charts NRXP vs RNACBanner chart's image
NRX Pharmaceuticals
Price$3.04
Change-$0.12 (-3.79%)
Volume$2.48K
Capitalization72.26M
Cartesian Therapeutics
Price$9.41
Change-$0.24 (-2.49%)
Volume$1.02K
Capitalization244.94M
NRXP vs RNAC Comparison Chart in %
NRXP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RNAC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
NRXP vs. RNAC commentary
Oct 17, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NRXP is a Hold and RNAC is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 17, 2025
Stock price -- (NRXP: $3.17 vs. RNAC: $9.70)
Brand notoriety: NRXP and RNAC are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NRXP: 40% vs. RNAC: 108%
Market capitalization -- NRXP: $75.35M vs. RNAC: $244.94M
NRXP [@Biotechnology] is valued at $75.35M. RNAC’s [@Biotechnology] market capitalization is $244.94M. The market cap for tickers in the [@Biotechnology] industry ranges from $104.58B to $0. The average market capitalization across the [@Biotechnology] industry is $2.05B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NRXP’s FA Score shows that 0 FA rating(s) are green whileRNAC’s FA Score has 0 green FA rating(s).

  • NRXP’s FA Score: 0 green, 5 red.
  • RNAC’s FA Score: 0 green, 5 red.
According to our system of comparison, NRXP is a better buy in the long-term than RNAC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NRXP’s TA Score shows that 5 TA indicator(s) are bullish while RNAC’s TA Score has 4 bullish TA indicator(s).

  • NRXP’s TA Score: 5 bullish, 5 bearish.
  • RNAC’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both NRXP and RNAC are a good buy in the short-term.

Price Growth

NRXP (@Biotechnology) experienced а -11.45% price change this week, while RNAC (@Biotechnology) price change was -5.18% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.40%. For the same industry, the average monthly price growth was +16.16%, and the average quarterly price growth was +80.98%.

Industries' Descriptions

@Biotechnology (-1.40% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RNAC($245M) has a higher market cap than NRXP($72.3M). RNAC has higher P/E ratio than NRXP: RNAC (1.98) vs NRXP (0.36). NRXP YTD gains are higher at: 38.182 vs. RNAC (-47.404). NRXP has higher annual earnings (EBITDA): -33.79M vs. RNAC (-118.73M). RNAC has more cash in the bank: 160M vs. NRXP (2.91M). NRXP has less debt than RNAC: NRXP (10.2M) vs RNAC (13.3M). RNAC has higher revenues than NRXP: RNAC (1.03M) vs NRXP (0).
NRXPRNACNRXP / RNAC
Capitalization72.3M245M30%
EBITDA-33.79M-118.73M28%
Gain YTD38.182-47.404-81%
P/E Ratio0.361.9818%
Revenue01.03M-
Total Cash2.91M160M2%
Total Debt10.2M13.3M77%
FUNDAMENTALS RATINGS
NRXP vs RNAC: Fundamental Ratings
NRXP
RNAC
OUTLOOK RATING
1..100
666
VALUATION
overvalued / fair valued / undervalued
1..100
43
Fair valued
99
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
4087
P/E GROWTH RATING
1..100
9341
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NRXP's Valuation (43) in the null industry is somewhat better than the same rating for RNAC (99) in the Biotechnology industry. This means that NRXP’s stock grew somewhat faster than RNAC’s over the last 12 months.

NRXP's Profit vs Risk Rating (100) in the null industry is in the same range as RNAC (100) in the Biotechnology industry. This means that NRXP’s stock grew similarly to RNAC’s over the last 12 months.

NRXP's SMR Rating (100) in the null industry is in the same range as RNAC (100) in the Biotechnology industry. This means that NRXP’s stock grew similarly to RNAC’s over the last 12 months.

NRXP's Price Growth Rating (40) in the null industry is somewhat better than the same rating for RNAC (87) in the Biotechnology industry. This means that NRXP’s stock grew somewhat faster than RNAC’s over the last 12 months.

RNAC's P/E Growth Rating (41) in the Biotechnology industry is somewhat better than the same rating for NRXP (93) in the null industry. This means that RNAC’s stock grew somewhat faster than NRXP’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NRXPRNAC
RSI
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
84%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
76%
Momentum
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
87%
MACD
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
88%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
87%
Bearish Trend 2 days ago
88%
Advances
ODDS (%)
Bullish Trend 10 days ago
83%
Bullish Trend 15 days ago
82%
Declines
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 7 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
76%
Aroon
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
86%
View a ticker or compare two or three
Interact to see
Advertisement
NRXP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RNAC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
REMYY5.340.24
+4.60%
Remy Cointreau SA
EBCOY13.240.43
+3.36%
Ebara Corp.
CRBBF9.46N/A
N/A
Corby Spirit and Wine Ltd.
PCLB31.01N/A
N/A
Pinnacle Bancshares, Inc.
ATCD1181.00N/A
N/A
Altair Corp.

NRXP and

Correlation & Price change

A.I.dvisor indicates that over the last year, NRXP has been closely correlated with RNAC. These tickers have moved in lockstep 86% of the time. This A.I.-generated data suggests there is a high statistical probability that if NRXP jumps, then RNAC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NRXP
1D Price
Change %
NRXP100%
-4.10%
RNAC - NRXP
86%
Closely correlated
-2.38%
NCNA - NRXP
85%
Closely correlated
-4.10%
TAOX - NRXP
84%
Closely correlated
-17.13%
ALLR - NRXP
81%
Closely correlated
-3.67%
PALI - NRXP
74%
Closely correlated
N/A
More

RNAC and

Correlation & Price change

A.I.dvisor indicates that over the last year, RNAC has been closely correlated with TAOX. These tickers have moved in lockstep 91% of the time. This A.I.-generated data suggests there is a high statistical probability that if RNAC jumps, then TAOX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RNAC
1D Price
Change %
RNAC100%
-2.38%
TAOX - RNAC
91%
Closely correlated
-17.13%
ALLR - RNAC
86%
Closely correlated
-3.67%
NRXP - RNAC
86%
Closely correlated
-4.10%
PALI - RNAC
81%
Closely correlated
N/A
OCUL - RNAC
49%
Loosely correlated
+2.22%
More